The ivermectin, a controversial antiparasitic drug that has presented itself as a potential treatment against COVID-19, does not support the recovery time in individuals living cases, in agreement with a JAMA student-controlled open airway.
The ivermectin itself can be used to treat parasitic gussets in humans as well as in animals through the scientific evidence of its efficacy against coronavirus is very difficult. Some studies have shown that the pharmacy can prevent viruses from replicating in cells. And last year, investigators in Australia found that, in elevated doses, in cellular cultures, the overexpression of SARS-CoV-2, the virus that causes covidia.
Dichos hallazgos alentaron el uso del medicamento contra la COVID-19, spesiaal en Amerika Latina.
“Ivermectina is currently being used extensively,” said Eduardo López Medina, a physician and investigator at the Pediatric Infectious Diseases Center in Cali, Colombia, who directed the new trial. “In many countries in the Americas and in other parts of the world it is part of the national co-operative lineages of covid”.
But the pharmacy caused division. Although some scientists believe that it has potential, others suspect that in order to effectively inhibit coronavirus, extremely high doses are required and possibly dangerous. Health officials also say that people who are desperate to treat coronavirus can take versions of the drugs they use to treat them, and that they are regularly used to prevent heartburn.
“I have a lot of opposing opinions about this, and some extremely oppressive opinions”, said Carlos Chaccour, researcher at the Barcelona Institute for Global Health without participating in the study. “I believe it has been converted into another hydroxychloroquine”.
But neither his defenders nor his critics have many rigorous dates to support his points of view. Bestaan pocos are well controlled by the effectiveness of the drug against COVID-19, although it is more hopeful in the next months. The treatment centers of the National Institutes of Health of the United States have advised that there is insufficient evidence “to recommend or discourage” the use of COVID-19 in patients.
In the new studio, López Medina and his colleagues will randomly assign to more than 400 people who have recently developed live COVID-19 drugs that take a five-day ivermectin dosing schedule. Find that covid sinomas last around 10 days in the persons receiving the pharmacy, in comparison with the 12 days of women receiving the placebo, a difference statistically insignificant.
The new clinical trial requires very necessary data for the debate on the use of ivermectin as treatment of COVID-19, dijo Regina Rabinovich, medical and investigator of global health at the School of Public Health TH Chan of Harvard, who did not participate the studio.
However, it has been observed that the study was relatively small and did not respond to the most urgent clinical question that is if ivermectin is able to prevent pregnancy or prevent death. “The duration of the symptoms can be seen as the most important non-clinical or public health parameter,” he said.
Investigators find that patients in the placebo group deteriorate when they participate in the study compared to the group of the ivermectin group, but the numbers are very small as they can reach a significant conclusion.
“I have a great signal here, and it will be interesting to see if this signal is real or not,” said López Medina. “But there is a tendency to respond in a mayoral statement”.
López Medina also commented that the study’s population was relatively young and salutary, with a premeditated edition of 37 years and some of the comorbidities that could make COVID-19 more exciting.
Currently, there are a number of major issues that may be the definitive answer, said Rabinovich, who commented that it was “totally neutral” regarding the potential utility of ivermectin. “Solo quiero datos porque hay un gran chaos en el campo”.